scout
|Videos|February 20, 2014

Dr. McKay Discusses Dutasteride in Prostate Cancer

Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, Boston, Massachusetts, explains the mechanism of action of dutasteride and its role in a phase II trial in which abiraterone acetate was combined with dutasteride in men with metastatic castration-resistant prostate cancer

Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, Boston, Massachusetts, explains the mechanism of action of dutasteride and its role in a phase II trial in which abiraterone acetate was combined with dutasteride in men with metastatic castration resistant prostate cancer (mCRPC).

McKay says dutasteride is a dual 5-α reductase inhibitor that prevents the conversion of testosterone to DHT, a more potent androgen.

Dutasteride is classically used for people with benign prostatic hypertrophy but was used in this phase II trial to try to decrease levels of DHT.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME